Selank 5mg

Selank 5mg – Ultra-Pure Heptapeptide for Advanced Research

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), also known as Selanc or TP-7, is a synthetic heptapeptide analogue of the endogenous immunomodulatory peptide tuftsin. It has been widely investigated for its roles in neuromodulation, immune regulation, and stress-response signalling in preclinical research models. 

Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has been examined in numerous peer-reviewed studies exploring GABAergic pathways, monoamine neurotransmitter balance, BDNF expression, and cytokine-mediated immune responses in animal and in vitro systems. 

⚙️

Peptide Specifications

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)  
• Molecular Formula: C₃₃H₅₇N₁₁O₉  
• Molecular Weight: ~751.9 g/mol  
• Appearance: White lyophilised powder  
• Purity: ≥99% (HPLC verified, batch-specific COA)
• Solubility: Readily soluble in sterile water; dilute acetic acid may be used where required for laboratory preparation (research use only)  
• Storage: 2–8°C (short term) / –18 to –20°C (long term) for the lyophilised peptide  
• Packaging: 5mg glass vial, supplied as lyophilised Selank heptapeptide, free from additives.

🧪

Scientific Insight & Synergistic Research

• Neuroplasticity & BDNF Pathways
  Preclinical data indicate that Selank can increase brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus following intranasal administration, suggesting involvement in synaptic plasticity and adaptive neural responses to stress.
• Gene Regulation, Monoamines & Immune Signalling
  Experimental studies report that Selank modulates expression of genes linked to GABAergic neurotransmission and related signalling pathways, and can influence concentrations of monoamine neurotransmitters (serotonin, dopamine, noradrenaline) in a strain-dependent manner in rodent brain tissue. 
  As a tuftsin analogue, Selank also demonstrates immunomodulatory activity, including effects on IL-6 and T-helper cell cytokine balance, aligning with its classification as a neuro-immunomodulatory peptide in research.  
  
• GABAergic Modulation & Synergistic Investigations
  Clinical and preclinical work from Russian groups describes an anxiolytic-like profile for Selank comparable to low-dose benzodiazepines, but without the sedation or dependence seen with those drugs within the scope of those studies. 
  Mechanistic findings suggest Selank can affect GABA_A receptor–related processes and inhibit certain enkephalin-degrading enzymes, a feature shared with the related peptide Semax. 
  In combined-pathway research, Selank is often evaluated alongside regulatory peptides such as Semax to characterise potential synergistic effects on GABAergic signalling, cognitive resilience, and stress-adaptation pathways in laboratory models.  

Published literature supports continued investigation of Selank within research programmes focused on neuro-immunomodulation, stress-responsive signalling, and adaptive peptide pathways in preclinical systems. 

🧪 For Laboratory Research Use Only

Not intended for human consumption or therapeutic application.